Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003), 49% at 3-week (p=0.006) and 41% at 3-month (p=0.011) post-ketamine Planning a Phase 3 clinical study to allow for FDA approval of KETARX (ketamine)…


Previous articlePT356 – Brom Rector – Investing in Psychedelics and The Rush to Improve on the Classics
Next articleBraxia Scientific Announces Court Approval of Class Action Settlement in Canada